4882 Perseus Proteomics
- 638
- +9+1.43%
Perseus Proteomics News
Perseus Proteomics: Announcements of individual stocks regarding the recording of non-operating income, non-operating expenses, and special losses.
Perseus Proteomics: Announcements of individual stocks regarding recognition of non-operating income, non-operating expenses, and extraordinary losses
Perseus Proteomics: Non-consolidated summary of Q1 financial results ending on March 31, 2025.
Perseus Proteomics: Announcement of the agreement on joint research on multi-specific antibodies with Yamagata University, Osaka City University, and the University of Tokyo.
Perseus Proteomics: Announcements of individual stocks: Yamagata University, Osaka City University, and Tokyo University of Agriculture and Technology have signed a joint research agreement on multi-specific antibodies.
Perseus Proteomics: Regarding inquiries about IR, please contact us by phone.
Perseus Proteomics: Announcements of individual stocks: Approval of PPMX-T002 research presentation at the EANM'24 annual meeting.
Perseus Proteomics: Announcements of individual stocks: The presentation of the research results of the PPMX-T002 at the EANM (European Association of Nuclear Medicine) 24th Annual Meeting has been accepted.
Perseus Proteomics: Announcements of individual stocks for the presentation of interim report on PPMX-T003 Phase I at the 14th Japan International Health Symposium in 2024.
Perseus Proteomics: At the 14th JSH International Symposium in 2024, an interim report on the clinical trial of PPMX-T003 was presented.
Perseus Proteomics: Announcements of individual stocks regarding the large exercise, completion of exercise, and monthly exercise status of the 28th subscription rights (with exercise price adjustment clause) through third-party allocation.
Perseus Proteomics: Announcements of individual stocks regarding monthly exercise status of 28th subscription rights (with exercise price adjustment clause) by third party allotment.
Perseus Proteomics: Announcements of individual stocks: Notice regarding the completion of Phase I clinical trial for genuine polycythemia vera (PV) - PPMX-T003
Perseus Proteomics: Announcements of individual stocks: PPMX-T003: Announcement of the end of Phase I trial for polycythemia vera (PV).
Perseus Proteomics: Announcements of individual stocks: Publication of a paper on ANKL therapy co-authored by Osaka University and Perseus Proteomics
Perseus Proteomics: Announcements of individual stocks: Co-authorship paper with Osaka University on Aggressive NK cell leukemia (ANKL), PPMX-T003.
Perseus Proteomics: Announcements of individual stocks regarding the large exercise of the 28th subscription rights (with exercise price adjustment clause) by third-party allocation.
Perseus Proteomics: Announced that the interim report of PPMX-T003 phase I at the 14th Japan International Health Symposium 2024 has been accepted for presentation.
Perseus Proteomics: Announcements of individual stocks: The mid-term report for the clinical trial of PPMX-T003 has been adopted at the 14th JSH International Symposium in 2024.
Perseus Proteomics: Announcements of individual stocks regarding the large exercise of the 28th subscription rights (with exercise price adjustment clause) by third-party allocation.
Analysis
Price Target
No Data
